Poly-L-lactic acid
Authority to supply poly-L-lactic acid (Sculptra®) through the Pharmaceutical Benefit Scheme (PBS), for the treatment of severe facial lipoatrophy caused by therapy for human immunodeficiency virus (HIV) infection, is available under Section 85 arrangements of the National Health Act 1953.
Restriction details
The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing poly-L-lactic acid (Sculptra®).
View a full transcript of the restriction details
Item details
All applications for treatment for facial administration only, of severe facial lipoatrophy caused by therapy for HIV infection must be made by an accredited injector who has received administration training by Sanofi-Aventis. Patients must be referred from the HIV physician to the accredited injector.
Dose
Poly-L-lactic acid is available in single vials containing 150 mg powder for injection.
Initial treatment
Initial treatment is limited to a maximum quantity of two vials and four repeats.
Maintenance treatment
Maintenance treatment is limited to one re-treatment (maximum quantity of two vials) every two years.
Patient eligibility
Patients must meet the relevant criteria as indicated in the restrictions and be eligible to receive PBS subsidised medicines.
Applications for treatment
All applications for treatment for eligible patients, by approved injectors, may be obtained by calling Medicare Australia on 1800 700 270** (option 4) between 8.00am and 5.00pm EST Monday to Friday.
For more information call 1800 700 270** (option 4) between 8.00am and 5.00pm EST Monday to Friday.
** Call charges apply from mobile or pay phones only.
Last updated: 19 March, 2010